Content about SILVER SPRING

SILVER SPRING, Md. The Food and Drug Administration has posted a new list of drugs from its Adverse Event Reporting System, designed to address potential signals of serious risks and new safety information about drugs on the market.

SILVER SPRING, Md. The Food and Drug Administration has approved an emergency contraceptive pill made by a French drug maker.

The FDA announced the approval of Ella (ulipristal acetate), designed to prevent pregnancy when taken orally within five days of unprotected sex or contraceptive failure, though it is not designed for routine use as a contraceptive.

SILVER SPRING, Md. The Food and Drug Administration on Aug. 9 posted a video outlining the revised prescription and over-the-counter labels for proton-pump inhibitors that include new safety information about a possible increased risk of fractures of the hip, wrist and spine with the use of these medications.

The video is a part of the FDA’s Drug Info Rounds, “a program by pharmacists for pharmacists,” and presented by the Division of Drug Information pharmacists division of FDA.

SILVER SPRING, Md. Some stolen inhalers for patients with asthma and chronic obstructive pulmonary disease have turned up in pharmacies, the Food and Drug Administration warned Friday.

Two lots of GlaxoSmithKline’s Advair Diskus (fluticasone propionate and salmeterol) were stolen from a warehouse near Richmond, Va., last August, with lot numbers 9ZP2255 – NDC 0173-0696-00 and 9ZP3325 – NDC 0173-0697-00. The inhalers recently found were the first from the stolen lots to turn up in commerce, the FDA said.

SILVER SPRING, Md. Prolonged use of a common class of drugs for treating digestive problems may increase the risk of bone fractures, the Food and Drug Administration said Tuesday.

The FDA issued a warning to consumers and healthcare professionals based on a review of several epidemiological studies that long-term use of prescription and OTC proton-pump inhibitors or use of the drugs in high doses could increase the risk of fractures of the hip, wrist and spine. Information about the possible risks will be included on revised product labels for PPIs, the FDA said.